DUS2
tRNA-dihydrouridine(20) synthase [NAD(P)+]-like
Also known as: DUS2_HUMAN, DUS2L, FLJ20399, SMM1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NX74
- Gene
- DUS2
- Ensembl
- ENSG00000167264
- Chromosome
- 16
- Canonical length
- 493 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
This gene encodes a cytoplasmic protein that catalyzes the conversion of uridine residues to dihydrouridine in the D-loop of tRNA. The resulting modified bases confer enhanced regional flexibility to tRNA. The encoded protein may increase the rate of translation by inhibiting an interferon-induced protein kinase. This gene has been implicated in pulmonary carcinogenesis. Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Nov 2012]
Canonical amino-acid sequenceUniProt
493 residues, UniProt reviewed canonical sequence.
>Q9NX74|DUS2
1 MILNSLSLCY HNKLILAPMV RVGTLPMRLL ALDYGADIVY CEELIDLKMI QCKRVVNEVL
61 STVDFVAPDD RVVFRTCERE QNRVVFQMGT SDAERALAVA RLVENDVAGI DVNMGCPKQY
121 STKGGMGAAL LSDPDKIEKI LSTLVKGTRR PVTCKIRILP SLEDTLSLVK RIERTGIAAI
181 AVHGRKREER PQHPVSCEVI KAIADTLSIP VIANGGSHDH IQQYSDIEDF RQATAASSVM
241 VARAAMWNPS IFLKEGLRPL EEVMQKYIRY AVQYDNHYTN TKYCLCQMLR EQLESPQGRL
301 LHAAQSSREI CEAFGLGAFY EETTQELDAQ QARLSAKTSE QTGEPAEDTS GVIKMAVKFD
361 RRAYPAQITP KMCLLEWCRR EKLAQPVYET VQRPLDRLFS SIVTVAEQKY QSTLWDKSKK
421 LAEQAAAIVC LRSQGLPEGR LGEESPSLHK RKREAPDQDP GGPRAQELAQ PGDLCKKPFV
481 ALGSGEESPL EGWLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DUS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 27 nTPM
Expression across tissuesHPA
Tissue
- testis: 27 nTPM
- tonsil: 19 nTPM
- lymph node: 18 nTPM
- spleen: 15 nTPM
- appendix: 12 nTPM
- esophagus: 11 nTPM
Single-cell type
- syncytiotrophoblasts: 74 nCPM
- early spermatids: 69 nCPM
- myonuclei: 57 nCPM
- neutrophils: 52 nCPM
- retinal ganglion cells: 46 nCPM
- neutrophil progenitors: 38 nCPM
Immune cell
- eosinophil: 90 nTPM
- memory B-cell: 57 nTPM
- naive B-cell: 49 nTPM
- non-classical monocyte: 38 nTPM
- classical monocyte: 29 nTPM
- neutrophil: 28 nTPM
Brain region
- white matter: 22 nTPM
- medulla oblongata: 20 nTPM
- cerebellum: 20 nTPM
- pons: 20 nTPM
- thalamus: 19 nTPM
- hypothalamus: 19 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.91
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.6
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- double-stranded RNA binding
- flavin adenine dinucleotide binding
- FMN binding
- NADPH binding
- protein kinase inhibitor activity
- tRNA binding
- tRNA dihydrouridine synthase activity
- tRNA-dihydrouridine20 synthase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aldolase-type TIM barrel
- Double-stranded RNA-binding domain
- tRNA-dihydrouridine synthase, conserved site
- DUS-like, FMN-binding domain
- Double-stranded RNA binding motif
- Dihydrouridine synthase (Dus)
- DUS2, double-stranded RNA binding domain
- tRNA-dihydrouridine synthase-like
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DUS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DUS2 as an antibody target. Whether an autoantibody or antibody against DUS2 could matter depends on whether native DUS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DUS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DUS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...